Correspondence 0001493152-24-031194 from AIxCrypto Holdings, Inc. (AIXC)
AIxCrypto Holdings, Inc.
Date: Aug. 12, 2024 · CIK: 0001460702 · Accession: 0001493152-24-031194
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272623
Letter
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300
Carlsbad, California 92008
August 12, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama, Jason Drory
Re: Qualigen Therapeutics, Inc.
Registration Statement on Form S-1
File 333-272623
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Qualigen Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 12, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Sichenzia Ross Ference Carmel LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to Ross D. Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel to the Company, at 646-838-1310 and that such effectiveness also be confirmed in writing.
Very
truly yours,
Qualigen
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Qualigen
Therapeutics, Inc.
5857 Owens Avenue, Suite 300
Carlsbad,
California 92008
August
12, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division of Corporation Finance
100
F Street, N.E.
Washington, D.C. 20549
Attn:
Doris Stacey Gama, Jason Drory
Re: Qualigen
Therapeutics, Inc.
Registration Statement on Form S-1
File 333-272623
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Qualigen Therapeutics, Inc. (the “Company”)
hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”)
be accelerated to August 12, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel,
Sichenzia Ross Ference Carmel LLP, request by telephone that such Registration Statement be declared effective at some other time. In
making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We
request that we be notified of such effectiveness by a telephone call to Ross D. Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel
to the Company, at 646-838-1310 and that such effectiveness also be confirmed in writing.
Very
truly yours,
Qualigen
Therapeutics, Inc.
By:
/s/
Michael S. Poirier
Michael
S. Poirier
Chief
Executive Officer and Chairman of the Board